Loading…
Passage Bio, Inc. is projected to decline to $4.36 by 2027, a -5% move from its current price of $4.57. PASG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.34 | $4.57 | $4.82 | +0.07% |
| Jul 14 | $4.25 | $4.58 | $4.93 | +0.14% |
| Jul 15 | $4.18 | $4.58 | $5.01 | +0.21% |
| Jul 16 | $4.13 | $4.58 | $5.09 | +0.28% |
| Jul 17 | $4.08 | $4.59 | $5.15 | +0.35% |
| Jul 18 | $4.04 | $4.59 | $5.21 | +0.42% |
| Jul 19 | $4.00 | $4.59 | $5.27 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.00 | $4.59 | $5.27 | +0.49% |
| Week 2 | $3.80 | $4.61 | $5.61 | +0.98% |
| Week 3 | $3.65 | $4.64 | $5.89 | +1.48% |
| Week 4 | $3.54 | $4.66 | $6.14 | +1.98% |
| Week 5 | $3.44 | $4.68 | $6.37 | +2.48% |
| Week 6 | $3.36 | $4.71 | $6.59 | +2.98% |
| Week 7 | $3.29 | $4.73 | $6.81 | +3.48% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Passage Bio, Inc. is a healthcare company that develops gene therapies for central nervous system diseases. It focuses on genetic medicines and advances programs to address specific neurodegenerative conditions, with PBFT02 aimed at FTD caused by progranulin deficiency and PBGM01 targeting infantile GM1 through a functional GLB1 gene.
The company’s pipeline also includes PBKR03 for Krabbe disease, PBML04 for metachromatic leukodystrophy, and PBAL05 for amyotrophic lateral sclerosis, with additional programs toward Huntington’s disease.
Passage Bio has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, along with a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Passage Bio, Inc. (PASG) is currently priced at $4.70 and trades in the healthcare sector as a small biotechnology-focused entity. Its market capitalization is $15.1M, and it carries a rank of 4965 among listed securities.
The near-term technical picture shows a bearish tilt, while the longer-run forecast points to meaningful upside through the end of the decade and into the 2050s. The 2026 forecast sits at an avg of $4.70 with a 0 ROI, while the trajectory through 2030, 2040, and 2050 envisions higher average prices and substantial ROI, culminating in an avg of $18.58 by 2050 and a 295.4 ROI at the high end.
Key intermediate levels: the 30-day range spans from $3.09 to $7.14, with a current price near $4.70. The forecast also shows the stock moving through ranges and outcomes with a bullish tilt later in the period, despite a bearish early outlook.
A major floor 29.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.3% below — buyers have tended to step in here.
The nearest ceiling, 33.9% above — a clean break opens room to run.
A major ceiling 160.2% above — clearing it would confirm fresh momentum.
Key PASG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PASG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.76 | Sell | $4.72 | Sell |
| MA 10 | $4.75 | Sell | $4.83 | Sell |
| MA 20 | $5.14 | Sell | $5.03 | Sell |
| MA 50 | $5.18 | Sell | $5.60 | Sell |
| MA 100 | $6.70 | Sell | $6.55 | Sell |
| MA 200 | $8.26 | Sell | $7.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.76 | Neutral |
| Stoch RSI (14) | 25.57 | Neutral |
| CCI (20) | -80.35 | Neutral |
| Williams %R (14) | -86.59 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -25.33 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 13.41 | Buy |
| TRIX (15) | -0.54 | Sell |
| Awesome (5,34) | -0.57 | Sell |
| Ultimate (7,14,28) | 37.40 | Neutral |
| Momentum (10) | 0.24 | Buy |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 4.76 | Sell |
| ADX (14) | 13.67 | Neutral |
| ATR (14) | 0.24 | Info |
The 30-day technical picture is negative, with a BEARISH sentiment and an RSI of 40. The stock trades below the SMA50 at $5.77 and below the SMA200 at $8.38, signaling near-term weakness.
Support is indicated at $4.33 and resistance at $6.12, framing a modest upside if price can push through the initial hurdle. The 30-day price range runs from $3.09 to $7.14, highlighting current volatility and a tendency toward downside pressure near the lower end.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.08 | $4.57 | $6.24 | 0% | Neutral | |
| $3.18 | $4.36 | $6.46 | -5% | Neutral | |
| $3.95 | $5.74 | $9.06 | +26% | Bullish | |
| $5.06 | $7.74 | $12.81 | +69% | Bullish | |
| $4.32 | $6.92 | $11.91 | +51% | Bullish | |
| $3.96 | $6.61 | $11.77 | +45% | Bullish | |
| $4.03 | $7.01 | $12.86 | +53% | Bullish | |
| $3.38 | $6.11 | $11.52 | +34% | Bullish | |
| $4.37 | $8.22 | $15.88 | +80% | Bullish | |
| $5.22 | $10.18 | $20.12 | +123% | Bullish | |
| $5.27 | $11.71 | $25.40 | +156% | Bullish | |
| $9.08 | $20.18 | $46.42 | +342% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.08 | $4.57 | $5.88 | +0.00% |
| August 2026 | $4.21 | $5.09 | $6.40 | +11.30% |
| September 2026 | $3.97 | $4.87 | $6.26 | -4.24% |
| October 2026 | $3.81 | $4.73 | $6.18 | -2.94% |
| November 2026 | $3.88 | $4.87 | $6.45 | +2.99% |
| December 2026 | $3.67 | $4.65 | $6.24 | -4.50% |
Click any year to see its month-by-month PASG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PASG to range from $4.08 to $6.24 through 2026. The $4.57 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PASG price prediction for 2027 points to an average of $4.36 (low $3.18, high $6.46) — a potential decline of -5% on today's $4.57. A consolidation phase looks the most probable path here.
In 2028, PASG is projected to trade between $3.95 and $9.06, averaging $5.74 — a potential gain of +26% from today's $4.57. That is up +32% on the projected 2027 average. Momentum favours further upside here.
Passage Bio, Inc.'s 2029 outlook centres on $7.74, within a $5.06 to $12.81 range. That is up +35% on the projected 2028 average. That marks a +69% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PASG could reach as high as $11.91, with a base case around $6.92 and support toward $4.32 — roughly +51% from $4.57. Momentum favours further upside here.
Expect PASG to range from $3.96 to $11.77 through 2031. The $6.61 average target implies a +45% move from current prices. That is -5% versus the projected 2030 average. Buyers look set to stay in control over this stretch.
The PASG price prediction for 2032 points to an average of $7.01 (low $4.03, high $12.86) — a potential gain of +53% on today's $4.57. Momentum favours further upside here.
In 2033, PASG is projected to trade between $3.38 and $11.52, averaging $6.11 — a potential gain of +34% from today's $4.57. That is -13% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Passage Bio, Inc.'s 2034 outlook centres on $8.22, within a $4.37 to $15.88 range. That is up +34% on the projected 2033 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2035, PASG could reach as high as $20.12, with a base case around $10.18 and support toward $5.22 — roughly +123% from $4.57. Buyers look set to stay in control over this stretch.
Expect PASG to range from $5.27 to $25.40 through 2040. The $11.71 average target implies a +156% move from current prices. That is up +15% on the projected 2035 average. Momentum favours further upside here.
The PASG price prediction for 2050 points to an average of $20.18 (low $9.08, high $46.42) — a potential gain of +342% on today's $4.57. Buyers look set to stay in control over this stretch.
Investing $1,000 in PASG today (≈ 218.818381 PASG) could be worth
$4,415.9
+$3,415.9 (+342%) by 2050 · US Dollar
Based on the average projected PASG price of $20.18 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PASGwould be worth at today's price.
$1,000 invested in PASG on Jul 10, 2025 (≈ 125.62814 PASG) would be worth
$574.12
-$425.88 (-42.6%) today · 0.57× · US Dollar
Based on a PASG entry price of $7.96 vs. today's $4.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.68 | $976.5 | -2.4% |
| 1 month ago | $5.13 | $890.84 | -10.9% |
| 3 months ago | $9.89 | $462.08 | -53.8% |
| 6 months ago | $17.91 | $255.16 | -74.5% |
| 1 year ago | $7.96 | $574.12 | -42.6% |
| All time (5.0y) ago | $256.8 | $17.8 | -98.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PASG forecast.
Our base-case forecast reaches $9.10 around 2035.
Implied market cap at $9.10: $29.24M
The multi-year forecast shows a gradual tightening of upside, with notable milestones in the 2030, 2040, and 2050 horizons. In 2030, the avg is $7.09 and the ROI is 50.8, with a max of $12.32. The 2040 projection strengthens to an avg of $11.83 and a ROI of 151.7, with a max near $25.99.
By 2050, the avg reaches $18.58 and the max $42.74, with a ROI of 295.4. These figures reflect a bullish trajectory over the long term, following a mid-period phase of more moderate gains.
The forecast includes a brief near-term dip, with 2027 showing an avg of $4.48 and a ROI of -4.8, suggesting some downside risk before the longer-run uptrend resumes. From 2028 onward, the outlook strengthens, with progressively higher avg values and positive ROIs through 2050. The overall path is bullish, but it carries the risk of near-term volatility and management of expectations given the early neutral to bearish readings.
Tap a question to reveal the answer.
The 2030 forecast lists a min of $4.37, an avg of $7.09, and a max of $12.32, with an ROIPct of 50.8 and a bullish sentiment.
Yes, the 2035 forecast shows a max of $20.05, an avg of $10.03, a min of $5.04, and a ROIPct of 113.3, with bullish sentiment.
Longer-term forecasts imply upside, with a 2040 avg of $11.83 and a ROIPct of 151.7, and a 2050 avg of $18.58 with a ROIPct of 295.4, though near-term readings include a neutral to bearish period (2026 avg $4.70, ROI 0 and 2027 avg $4.48, ROI -4.8). The figures are estimates, not guarantees.
The 2050 forecast shows an avg of $18.58, a min of $8.36, a max of $42.74, with a ROIPct of 295.4 and bullish sentiment.
The 30-day range is $3.09 to $7.14, with an RSI of 40, and pricing indicators: SMA50 at $5.77 and SMA200 at $8.38. Support is $4.33 and resistance is $6.12, with the overall tone labeled bearish.
Passage Bio, Inc. Community Discussion
0Share your Passage Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.